Skip to main content

Tevogen Bio Holdings Inc

Filed Jun 21, 2024.

View on SEC.gov

About this filing

A company's registration of shares for sale to the public, often for a first offering. It describes the business, its risks and how the company plans to use the money.

period unavailable · Filed Jun 21, 2024

TVGN$5.59+0.5%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This prospectus contains statements that constitute “forward-looking statements” for purposes of the federal securities laws. Forward-looking statements include, but are not limited to, statements that discuss future events, hopes, expectations, beliefs, intentions, or strategies regarding the future, projections of results of operations or financial condition, changes in the markets in which we compete, and trends in our business. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions or their opposites may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this prospectus may include, for example, statements about:

●the development of, potential benefits of, and patient access to our product candidates for the treatment of infectious diseases, cancer, and neurological disorders, including TVGN 489 for the treatment of COVID-19 and Long COVID;
●our ability to develop additional product candidates, including through the use of our ExacTcellTM platform;
●the anticipated benefits of ExacTcell;
●our expectations regarding our future clinical trials;
●our manufacturing plans;
●our ability to generate revenue in the future;
●our ability to manage, grow, and diversify our business and execute our business initiatives and strategy;
●expectations regarding the healthcare and biopharmaceutical industries;
●the potential liquidity and trading of our securities; and
●the future business, operations, and financial performance of our company.

The forward-looking statements contained in this prospectus are based on management’s current expectations, assumptions, and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among others:

●the effect of the Business Combination on our business relationships, operating results, and business generally;
●the outcome of any legal proceedings that may be instituted against us related to the Business Combination;
●changes in the markets in which we compete, including with respect to its competitive landscape, technology evolution, or regulatory changes;
●changes in domestic and global general economic conditions;
●we may not be able to execute our growth strategies or may experience difficulties in managing our growth and expanding operations;
●we may not be able to develop and maintain effective internal controls;
●costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination;
●we may fail to achieve our commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition and our ability to grow and manage growth economically and hire and retain key employees;

iii

●we may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services;
●risks related to our ability to develop, license, or acquire new therapeutics;
●we will need to raise additional capital, which may not be available on acceptable terms or at all, in order to execute our business plan;
●the risk of regulatory lawsuits or proceedings relating to our business;
●uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials;
●risks related to regulatory review and approval and commercial development;
●risks associated with intellectual property protection;
●our limited operating history;
●risks related to the failure to satisfy continued listing requirements of The Nasdaq Stock Market LLC (“Nasdaq”), including maintaining a minimum closing bid price of $1.00 per share pursuant to Nasdaq Listing Rule 5550(a)(2); and
●those factors discussed under the heading “Risk Factors” below.

Forward-looking statements should be considered in light of these factors and the factors described elsewhere in this prospectus, including in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” You should read these factors and the other cautionary statements made in this prospectus as being applicable to all related forward-looking statements wherever they appear in this prospectus. These risks are not exhaustive. New risks emerge from time to time and it is not possible to predict or identify all such risks, nor can we assess the impact of all such risks on our business or the extent to which any risk or combination of risks may cause actual results to differ materially from those contained in any forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable law

In addition, statements of belief and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information currently available to us, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements.

iv

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.